MedTrace Logo

AI-Driven Personalization of End-of-Life Care for the Elderly

NCT07027618 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2025-06-18

No results posted yet for this study

Summary

This study aims to evaluate the effectiveness of an artificial intelligence (AI)-based software in personalizing high-quality end-of-life care for elderly patients. As the elderly population grows, providing tailored and quality care during the final stages of life becomes increasingly important. This AI software continuously monitors vital signs and behaviors through wearable sensors, offers smart medication reminders, alerts the care team to potential risks, and provides personalized care plans along with psychological and social support.

The study is designed as a randomized controlled trial comparing two groups: one receiving standard end-of-life care and the other using the AI software. Key outcomes include improving quality of life, reducing adverse events like falls and emergency hospitalizations, increasing patient and family satisfaction, improving medication management, and reducing caregiver burden. Data will be collected over six months to assess these effects. The results will help determine whether AI technology can enhance end-of-life care for seniors and support families and healthcare providers.

Conditions

  • Artificial Intelligence (AI)
  • Dementia
  • Palliative Care

Interventions

BEHAVIORAL

AI-based Software for Personalized End-of-Life Care

This intervention involves the use of an AI-powered software system designed to personalize end-of-life care for elderly patients. The software continuously monitors vital signs and behavior through wearable sensors, sends smart medication reminders, issues preventive alerts to care providers, delivers customized care plans, and provides psychological and social support through communication features.

Sponsors & Collaborators

  • Baqiyatallah Medical Sciences University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-31
Primary Completion
2026-08-31
Completion
2026-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07027618 on ClinicalTrials.gov